# A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer

Source: https://onco.cc/trials/nct07407283/  
OnCo record `nct07407283` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Rezvilutamide, Tazemetostat in prostate cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.

## Summary

A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer is a phase 1/2 interventional study registered as NCT07407283 by Jiangsu HengRui Medicine Co., Ltd., with 100 participants planned, started 2026-04-08 and due to reach its primary completion in 2027-11. Interventions recorded: SHR-4394, Rezvilutamide, HRS-5041 Tablets, Tazemetostat. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07407283
- Phase: 1/2
- Setting: A Multicenter, Open-label, Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of SHR-4394 in Combination With Anti-tumor Therapy in Participants With Prostate Cancer
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT07407283: https://clinicaltrials.gov/study/NCT07407283

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Rezvilutamide](https://onco.cc/drugs/rezvilutamide/), [Tazemetostat](https://onco.cc/drugs/tazemetostat/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07407283.json